deltatrials
Completed PHASE3 NCT00007501

Shingles Prevention Study

CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications

Sponsor: Merck Sharp & Dohme LLC

Conditions Herpes Zoster Postherpetic Neuralgia
Interventions Placebo Varicella-zoster vaccine
Updated 8 times since 2017 Last updated: Jul 2, 2013 Started: Nov 30, 1998 Primary completion: Apr 30, 2004 Completion: Feb 28, 2011

A PHASE3 clinical study on Herpes Zoster and Postherpetic Neuralgia, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 8 data snapshots since 1998. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Aug 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • US Department of Veterans Affairs
Data source: VA Office of Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Ann Arbor, United States, Baltimore, United States, Bethesda, United States, Birmingham, United States, Boston, United States, Denver, United States, Durham, United States, Hines, United States, Houston, United States and 12 more location s